Render Target: STATIC
Render Timestamp: 2024-09-16T10:06:32.158Z
Commit: 195d6e018d1f29a59e5c111fed767382e8d7f01b
1% for the planet logo
PDP - Template Name: Monoclonal Antibody
PDP - Template ID: *******c5e4b77
R Recombinant
Recombinant: Superior lot-to-lot consistency, continuous supply, and animal-free manufacturing.

MYH11 (E4Q4L) Rabbit mAb #79479

Filter:
  • WB
  • IF

    Supporting Data

    REACTIVITY H M R
    SENSITIVITY Endogenous
    MW (kDa) 270
    Source/Isotype Rabbit IgG
    Application Key:
    • WB-Western Blotting 
    • IF-Immunofluorescence 
    Species Cross-Reactivity Key:
    • H-Human 
    • M-Mouse 
    • R-Rat 

    Product Information

    Product Usage Information

    Application Dilution
    Western Blotting 1:1000
    Immunofluorescence (Frozen) 1:400 - 1:1600
    Immunofluorescence (Immunocytochemistry) 1:200 - 1:800

    Storage

    Supplied in 10 mM sodium HEPES (pH 7.5), 150 mM NaCl, 100 µg/mL BSA, 50% glycerol, and less than 0.02% sodium azide. Store at –20°C. Do not aliquot the antibody.

    Protocol

    Specificity / Sensitivity

    MYH11 (E4Q4L) Rabbit mAb recognizes endogenous levels of total MYH11 protein.

    Species Reactivity:

    Human, Mouse, Rat

    Source / Purification

    Monoclonal antibody is produced by immunizing animals with a synthetic peptide corresponding to residues surrounding Leu639 of human MYH11 protein.

    Background

    MYH11 encodes the smooth muscle myosin heavy chain (SMMHC), a major specific contractile protein produced in smooth muscle (1). Mutations in MYH11 cause medial degeneration of the aorta with very low smooth muscle cell (SMC) content. Disease symptoms include aortic stiffness, aneurysm/dissection, and ductus arteriosus (2). One of the most frequent chromosomal translocations associated with acute myeloid leukemia (AML) is the fusion of CBFB, encoding the core binding protein CBFβ transcriptional factor, to MYH11 (3). This gene fusion event results in a chimeric protein that suppresses the transactivation mediated by CBF/AML-1, impairs the process of normal hematopoietic differentiation (4,5), and creates preleukemic myeloid progenitors that can be targets for AML transformation (6).
    For Research Use Only. Not For Use In Diagnostic Procedures.
    Cell Signaling Technology is a trademark of Cell Signaling Technology, Inc.
    All other trademarks are the property of their respective owners. Visit our Trademark Information page.